Skip to main content

Table 1 Subjects' Demographic Data at Study Entry

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

  Study population (n = 74)
Male sex [No. (%)] 61 (82)
Race  
   African American [No. (%)] 55 (74)
   White [No. (%)] 17 (23)
   Hispanic [No. (%)] 2 (3)
†On LPV/r tablet at entry  
   No [No. (%)] 49 (66)
   Yes [No. (%)] 25 (34)
On anti-diarrheal drug  
   No [No. (%)] 67 (92)
   Yes [No. (%)] 6 (8)
On lipid lowering drug  
   No [No. (%)] 54 (74)
   Yes [No. (%)] 19 (26)
Median age [years (IQR)] 43 (39-47)
Median weight [Kg (IQR)] 80.5 (69.60-88.60)
Median HIV-1 RNA [copies/ml (IQR)] 0.135 (0.05-0.70)
Median CD4 T-cell counts [cell/μl (IQR)] 294 (157-455)
  1. LPV/r, lopinavir/ritonavir; SGC, soft gel capsule; IQR, inter-quartile range.